Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 75 | 2022 | 13499 | 1.500 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 42 | 2018 | 5394 | 1.240 |
Why?
|
Movement | 12 | 2016 | 1490 | 1.120 |
Why?
|
Fluorodeoxyglucose F18 | 11 | 2018 | 2054 | 0.950 |
Why?
|
Carcinoma, Small Cell | 16 | 2003 | 419 | 0.900 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 14 | 2018 | 1679 | 0.890 |
Why?
|
Esophageal Neoplasms | 16 | 2016 | 1663 | 0.890 |
Why?
|
Respiration | 8 | 2013 | 1661 | 0.750 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2014 | 454 | 0.660 |
Why?
|
Radiation Pneumonitis | 5 | 2018 | 100 | 0.620 |
Why?
|
Radiotherapy Dosage | 22 | 2017 | 2916 | 0.560 |
Why?
|
Radiopharmaceuticals | 5 | 2014 | 2736 | 0.530 |
Why?
|
Positron-Emission Tomography | 8 | 2018 | 6668 | 0.480 |
Why?
|
Neoadjuvant Therapy | 11 | 2016 | 2902 | 0.440 |
Why?
|
Radiotherapy, Conformal | 5 | 2014 | 549 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 16 | 2022 | 20757 | 0.380 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.360 |
Why?
|
Thymus Neoplasms | 7 | 2013 | 272 | 0.360 |
Why?
|
Combined Modality Therapy | 42 | 2011 | 8535 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2018 | 9412 | 0.330 |
Why?
|
Radiation Injuries | 7 | 2018 | 1198 | 0.320 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2016 | 11873 | 0.320 |
Why?
|
Thymoma | 6 | 2013 | 186 | 0.320 |
Why?
|
Radiotherapy | 10 | 2018 | 1501 | 0.280 |
Why?
|
Cisplatin | 19 | 2016 | 1658 | 0.260 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 798 | 0.240 |
Why?
|
Glucose | 6 | 2014 | 4351 | 0.230 |
Why?
|
Neoplasm Staging | 23 | 2018 | 11221 | 0.230 |
Why?
|
Amifostine | 1 | 2003 | 39 | 0.230 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 87 | 0.220 |
Why?
|
DNA Repair | 1 | 2011 | 2050 | 0.200 |
Why?
|
Lung | 8 | 2018 | 10094 | 0.200 |
Why?
|
Respiratory Mechanics | 1 | 2006 | 721 | 0.200 |
Why?
|
Paclitaxel | 5 | 2018 | 1728 | 0.180 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1232 | 0.180 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2906 | 0.180 |
Why?
|
Adenocarcinoma | 12 | 2011 | 6371 | 0.180 |
Why?
|
Aged | 59 | 2022 | 171446 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 12 | 2011 | 4050 | 0.160 |
Why?
|
Carcinoma, Bronchogenic | 3 | 1986 | 86 | 0.160 |
Why?
|
Aged, 80 and over | 26 | 2018 | 59598 | 0.160 |
Why?
|
Imaging, Three-Dimensional | 3 | 2008 | 4063 | 0.150 |
Why?
|
Nuclear Proteins | 2 | 2011 | 5799 | 0.150 |
Why?
|
Tomography, Emission-Computed | 7 | 2004 | 1126 | 0.140 |
Why?
|
Middle Aged | 60 | 2018 | 223422 | 0.140 |
Why?
|
Carboplatin | 3 | 2018 | 791 | 0.130 |
Why?
|
Fluorouracil | 11 | 2006 | 1652 | 0.130 |
Why?
|
Lymph Nodes | 1 | 2007 | 3472 | 0.130 |
Why?
|
Survival Rate | 14 | 2017 | 12828 | 0.130 |
Why?
|
Radiosurgery | 2 | 2018 | 1330 | 0.130 |
Why?
|
Male | 64 | 2018 | 364641 | 0.130 |
Why?
|
Humans | 99 | 2022 | 767991 | 0.120 |
Why?
|
Tumor Burden | 5 | 2016 | 1904 | 0.120 |
Why?
|
Thymectomy | 2 | 2013 | 200 | 0.120 |
Why?
|
Female | 66 | 2018 | 397113 | 0.120 |
Why?
|
Probability | 3 | 2013 | 2479 | 0.120 |
Why?
|
Sensitivity and Specificity | 6 | 2014 | 14718 | 0.120 |
Why?
|
Spinal Cord Neoplasms | 2 | 1987 | 263 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 319 | 0.110 |
Why?
|
Pneumonectomy | 4 | 2009 | 1148 | 0.110 |
Why?
|
Lung Injury | 1 | 2018 | 433 | 0.110 |
Why?
|
Respiratory Function Tests | 4 | 1994 | 1695 | 0.100 |
Why?
|
Esophagitis | 3 | 2003 | 164 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2011 | 6228 | 0.090 |
Why?
|
Lymphatic Metastasis | 4 | 2010 | 2908 | 0.090 |
Why?
|
Lung Diseases | 2 | 1994 | 1944 | 0.090 |
Why?
|
Etoposide | 5 | 2013 | 640 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 276 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2016 | 4857 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2085 | 0.090 |
Why?
|
Deoxyglucose | 3 | 1996 | 333 | 0.080 |
Why?
|
Protein Array Analysis | 1 | 2011 | 399 | 0.080 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2011 | 428 | 0.080 |
Why?
|
Adult | 37 | 2018 | 223583 | 0.080 |
Why?
|
ras Proteins | 1 | 2014 | 1054 | 0.080 |
Why?
|
Lymphatic Irradiation | 1 | 2009 | 115 | 0.080 |
Why?
|
Preoperative Care | 4 | 2013 | 2256 | 0.080 |
Why?
|
Carcinoma | 3 | 2013 | 2330 | 0.070 |
Why?
|
Carcinoma, Large Cell | 2 | 2007 | 114 | 0.070 |
Why?
|
Feasibility Studies | 6 | 2018 | 5314 | 0.070 |
Why?
|
Prospective Studies | 10 | 2017 | 54924 | 0.070 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 202 | 0.070 |
Why?
|
Fluorine Radioisotopes | 3 | 1996 | 425 | 0.070 |
Why?
|
Brain Neoplasms | 5 | 2014 | 9116 | 0.070 |
Why?
|
Artifacts | 2 | 2008 | 1923 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1621 | 0.070 |
Why?
|
Mediastinum | 1 | 2007 | 272 | 0.070 |
Why?
|
Treatment Outcome | 17 | 2014 | 65364 | 0.060 |
Why?
|
Disease-Free Survival | 4 | 2016 | 6843 | 0.060 |
Why?
|
Consensus | 1 | 2016 | 3210 | 0.060 |
Why?
|
Point Mutation | 1 | 2011 | 1594 | 0.060 |
Why?
|
Radiometry | 2 | 2018 | 819 | 0.060 |
Why?
|
Monte Carlo Method | 2 | 2013 | 1259 | 0.060 |
Why?
|
Scattering, Radiation | 2 | 2018 | 489 | 0.060 |
Why?
|
Retrospective Studies | 16 | 2018 | 81746 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2008 | 3553 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2002 | 876 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2013 | 3618 | 0.060 |
Why?
|
Pericardial Effusion | 1 | 1987 | 246 | 0.060 |
Why?
|
Dura Mater | 1 | 1987 | 293 | 0.060 |
Why?
|
Risk | 5 | 2018 | 9609 | 0.060 |
Why?
|
Esophagogastric Junction | 3 | 2016 | 350 | 0.060 |
Why?
|
Radiotherapy, High-Energy | 2 | 1981 | 228 | 0.050 |
Why?
|
Prognosis | 10 | 2011 | 29979 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2008 | 1788 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2011 | 3601 | 0.050 |
Why?
|
Regression Analysis | 1 | 2013 | 6339 | 0.050 |
Why?
|
Troponin T | 1 | 2008 | 787 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 6517 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4525 | 0.050 |
Why?
|
Reference Values | 1 | 2009 | 4938 | 0.050 |
Why?
|
Smoking | 1 | 2018 | 9089 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2889 | 0.050 |
Why?
|
Treatment Failure | 3 | 2003 | 2660 | 0.050 |
Why?
|
Organs at Risk | 2 | 2016 | 367 | 0.050 |
Why?
|
Camptothecin | 2 | 2016 | 599 | 0.050 |
Why?
|
Genotype | 2 | 2014 | 13042 | 0.040 |
Why?
|
Radiation Dosage | 3 | 2018 | 1967 | 0.040 |
Why?
|
Follow-Up Studies | 10 | 2017 | 39345 | 0.040 |
Why?
|
Lymphatic System | 1 | 2002 | 251 | 0.040 |
Why?
|
Fibrosarcoma | 1 | 2002 | 313 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2018 | 2358 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2018 | 20218 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1751 | 0.040 |
Why?
|
Clinical Trials as Topic | 5 | 2016 | 8052 | 0.040 |
Why?
|
Melanoma, Experimental | 1 | 2002 | 559 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2003 | 1335 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2001 | 15442 | 0.040 |
Why?
|
Meningeal Neoplasms | 1 | 1987 | 1253 | 0.040 |
Why?
|
Cranial Fossa, Posterior | 2 | 1987 | 134 | 0.030 |
Why?
|
Survival Analysis | 6 | 2008 | 10098 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 9016 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 153 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2008 | 5151 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1996 | 284 | 0.030 |
Why?
|
Photons | 1 | 2018 | 594 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7876 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9614 | 0.030 |
Why?
|
Time Factors | 9 | 2013 | 40214 | 0.030 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 1994 | 116 | 0.030 |
Why?
|
Postoperative Period | 3 | 1991 | 1826 | 0.030 |
Why?
|
Nausea | 1 | 2016 | 682 | 0.030 |
Why?
|
Protons | 1 | 2018 | 1114 | 0.030 |
Why?
|
Antineoplastic Agents | 5 | 2003 | 13658 | 0.030 |
Why?
|
Computer Simulation | 1 | 2006 | 6283 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 1999 | 1429 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2005 | 3389 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 16041 | 0.020 |
Why?
|
Vinblastine | 3 | 2002 | 487 | 0.020 |
Why?
|
Radiography | 3 | 2009 | 6983 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 313 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1996 | 584 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2011 | 10396 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8637 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2016 | 640 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 12536 | 0.020 |
Why?
|
Mesothelioma | 1 | 1996 | 774 | 0.020 |
Why?
|
North America | 1 | 2013 | 1289 | 0.020 |
Why?
|
Lymphoma | 1 | 1979 | 1897 | 0.020 |
Why?
|
Remission Induction | 2 | 2008 | 2409 | 0.020 |
Why?
|
Safety | 1 | 1994 | 1159 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2005 | 4362 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 1994 | 1831 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 1990 | 384 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2708 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 592 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4030 | 0.020 |
Why?
|
Young Adult | 4 | 2018 | 60048 | 0.020 |
Why?
|
Linear Models | 1 | 2018 | 5884 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12075 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3237 | 0.020 |
Why?
|
Esophagus | 2 | 2010 | 1042 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1987 | 370 | 0.020 |
Why?
|
Exhalation | 1 | 2007 | 185 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 618 | 0.020 |
Why?
|
Mediastinal Diseases | 1 | 2007 | 91 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1760 | 0.020 |
Why?
|
Risk Factors | 5 | 2018 | 74936 | 0.020 |
Why?
|
Algorithms | 2 | 2005 | 14163 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 788 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1999 | 3007 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2863 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6809 | 0.010 |
Why?
|
Water | 1 | 2009 | 1421 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3628 | 0.010 |
Why?
|
Pilot Projects | 2 | 2013 | 8740 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 1481 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2923 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2002 | 125 | 0.010 |
Why?
|
Lymphography | 1 | 2002 | 189 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1980 | 15 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 1999 | 36742 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 2002 | 915 | 0.010 |
Why?
|
Immunoenzyme Techniques | 2 | 1996 | 1698 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26375 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 897 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 13000 | 0.010 |
Why?
|
Cough | 1 | 2004 | 598 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2005 | 877 | 0.010 |
Why?
|
Extracellular Space | 1 | 2002 | 563 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2824 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 21532 | 0.010 |
Why?
|
Taxoids | 1 | 2003 | 665 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 671 | 0.010 |
Why?
|
Postoperative Care | 1 | 1986 | 1480 | 0.010 |
Why?
|
Technetium Tc 99m Exametazime | 1 | 1999 | 61 | 0.010 |
Why?
|
Peptides | 1 | 1991 | 4354 | 0.010 |
Why?
|
Vesicular Transport Proteins | 1 | 2002 | 377 | 0.010 |
Why?
|
Cerebral Arterial Diseases | 1 | 1999 | 82 | 0.010 |
Why?
|
Pressure | 1 | 2002 | 1172 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 384 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2002 | 2014 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2002 | 1617 | 0.010 |
Why?
|
Blood Volume | 1 | 1999 | 545 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9666 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1988 | 4904 | 0.010 |
Why?
|
Microscopy | 1 | 2002 | 909 | 0.010 |
Why?
|
Mutation | 2 | 2011 | 30211 | 0.010 |
Why?
|
Membrane Transport Proteins | 1 | 2002 | 1037 | 0.010 |
Why?
|
Animals | 3 | 2003 | 169222 | 0.010 |
Why?
|
Mice, Nude | 1 | 2002 | 3620 | 0.010 |
Why?
|
Sarcoma | 1 | 1987 | 1804 | 0.010 |
Why?
|
Biopsy | 1 | 2007 | 6786 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2009 | 5349 | 0.010 |
Why?
|
Arterial Occlusive Diseases | 1 | 1999 | 744 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 1987 | 2540 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6119 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2201 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 1999 | 969 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1140 | 0.010 |
Why?
|
United States | 1 | 2022 | 73027 | 0.010 |
Why?
|
Ki-67 Antigen | 1 | 1996 | 630 | 0.010 |
Why?
|
Patient Care Planning | 1 | 1999 | 905 | 0.010 |
Why?
|
Neoplasms | 1 | 2002 | 22365 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 1993 | 21206 | 0.010 |
Why?
|
Blood Vessels | 1 | 1998 | 1110 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1999 | 1484 | 0.010 |
Why?
|
Gastrin-Releasing Peptide | 1 | 1991 | 36 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1979 | 1374 | 0.010 |
Why?
|
Cranial Irradiation | 1 | 1994 | 393 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1979 | 1179 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15831 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1992 | 642 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2003 | 10757 | 0.010 |
Why?
|
Forecasting | 1 | 2000 | 2945 | 0.010 |
Why?
|
Blood Glucose | 2 | 1996 | 6429 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 1991 | 225 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1999 | 2726 | 0.000 |
Why?
|
RNA, Neoplasm | 1 | 1991 | 748 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 2002 | 11068 | 0.000 |
Why?
|
Image Enhancement | 1 | 1999 | 2880 | 0.000 |
Why?
|
Acute Disease | 1 | 1999 | 7241 | 0.000 |
Why?
|
Cohort Studies | 1 | 2011 | 41749 | 0.000 |
Why?
|
Infusions, Intravenous | 1 | 1993 | 2227 | 0.000 |
Why?
|
In Situ Hybridization | 1 | 1991 | 1892 | 0.000 |
Why?
|
Cell Cycle | 1 | 1996 | 2932 | 0.000 |
Why?
|
Doxorubicin | 1 | 1994 | 2234 | 0.000 |
Why?
|
Risk Assessment | 1 | 2008 | 24314 | 0.000 |
Why?
|
Contrast Media | 1 | 1999 | 5330 | 0.000 |
Why?
|
Particle Accelerators | 1 | 1986 | 173 | 0.000 |
Why?
|
Thorax | 1 | 1987 | 557 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1987 | 2227 | 0.000 |
Why?
|
Quality of Life | 1 | 1982 | 13489 | 0.000 |
Why?
|
Gene Expression | 1 | 1991 | 7597 | 0.000 |
Why?
|
Models, Biological | 1 | 1994 | 9493 | 0.000 |
Why?
|
Hydrocortisone | 1 | 1986 | 1840 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1991 | 12797 | 0.000 |
Why?
|
Mice | 1 | 2002 | 82024 | 0.000 |
Why?
|
Adolescent | 1 | 1994 | 89155 | 0.000 |
Why?
|
Brain | 1 | 1987 | 27366 | 0.000 |
Why?
|